Role of recombinant human erythropoietin in the treatment of cancer-related anaemia

Journal Title: OncoReview - Year 2017, Vol 7, Issue 2

Abstract

Anaemia is one of the most frequently diagnosed complications in cancer patients and also occurs during the course of cancer treatment. The condition can be observed in as many as 60–70% of patients who receive chemotherapy or radiotherapy. As a cancer symptom, it is found in 30% of cases and is particularly severe when accompanied by kidney failure. In patients undergoing cancer therapy, anaemia is treated with PRBC transfusions and/or recombinant human erythropoietin. The article discusses 3 case studies of patients with late-stage cancer (pleural mesothelioma, urothelial kidney carcinoma, and lung carcinoma), who suffered from moderate to severe anaemia during aggressive treatment with chemo- and radiotherapy. All 3 patients were treated with erythropoietin, which made it possible for them to stay on chemotherapy and/or undergo radiotherapy. Thanks to erythropoietin, they did not require PRBC transfusions and their general condition and quality of life improved. They tolerated the treatment well and no complications were observed.

Authors and Affiliations

Tomasz Jankowski

Keywords

Related Articles

Novel oral anticoagulants in the treatment of cancer patients

Cancer and its treatment are well-recognized risk factors for venous thromboembolism. The risk of thrombotic complications increases 4–7-fold in cancer patients and coexistence of both pathologies is associated with shor...

Invasive fungal infection in an acute myeloid leukaemia patient

Invasive fungal infections (IFI) are one of the most severe complications of treatment in patients with acute myeloid leukaemia (AML) that are diagnosed during the myelosuppression period following intensive chemotherapy...

Nuclear medicine diagnostic tools for early detection of myocardial damage in treated breast cancer patients

The most severe side effect in treated patients with breast cancer is treatment-induced cardiotoxicity, leading to chronic heart failure or CAD, and worsening the patient’s quality of life. The early detection and medica...

Download PDF file
  • EP ID EP189865
  • DOI 10.24292/01.OR.300617.8
  • Views 214
  • Downloads 0

How To Cite

Tomasz Jankowski (2017). Role of recombinant human erythropoietin in the treatment of cancer-related anaemia. OncoReview, 7(2), 98-103. https://europub.co.uk./articles/-A-189865